Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.51 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28561362 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL797638 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL28545037 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL6114801 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL6115276 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL29903853 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL6114960 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL2514450 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL6115301 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 | |
| SCHEMBL29369286 | 1.00 | KCNH2 (0.61) | KCNH2GPBAR1TLR8CYSLTR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057852-A1 | Spectrometric Analysis of Microbes | MICROMASS UK LIMITED (GB) | 2018-03-01 | — | — | US | disclosed |
| CN-107667288-A | Spectral analysis of microorganisms | 英国质谱公司 | 2018-02-06 | — | — | CN | disclosed |
| CN-104211620-B | The autofrettage of bi-quaternary ammonium salt and its intermediate | Wako-chem Industries Co., Ltd. (JP) | 2016-05-25 | — | — | CN | disclosed |
| EP-2821395-A2 | Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery | Wako Pure Chemical Industries, Ltd. (JP) | 2015-01-07 | — | — | EP | disclosed |
| CN-104211620-A | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | WAKO PURE CHEM IND LTD | 2014-12-17 | — | — | CN | disclosed |
| US-8716513-B2 | Process for production of bis-quaternary ammonium salt, and novel intermediate | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-05-06 | — | — | US | disclosed |
| EP-2463266-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | Wako Pure Chemical Industries, Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| CN-102482197-A | Process for producing diquaternary ammonium salt and novel intermediate | WAKO PURE CHEM IND LTD | 2012-05-30 | — | — | CN | disclosed |
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| WO-2007008769-A2 | USE OF PSEUDAN AND PSEUDAN INCLUSION BODIES | GEORGE MASON UNIVERSITY (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2005069989-A2 | METHODS FOR IDENTIFYING CANDIDATE COMPOUNDS FOR TREATING, REDUCING, OR PREVENTING PATHOGENIC INFECTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-0529452-B1 | 1,7-Condensed 3-(piperazinoalkyl)indol derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | SOLVAY PHARM GMBH (DE) | 1998-11-11 | — | — | EP | disclosed |
| US-5324725-A | Antiinflammatory agent, antiallergen | KALI-CHEMIE PHARMA GMBH (DE) | 1994-06-28 | — | — | US | disclosed |
| CN-1069732-A | 1, the 2-that 7-a pair of horses going side by side is closed (piperazine alkyl) indole derivatives and preparation method and intermediate product and the medicament that contains these compounds | KALI CHEMIE PHARMA GMBH (DE) | 1993-03-10 | — | — | CN | disclosed |
| EP-0529452-A2 | 1,7-Condensed 2-(piperazinoalkyl)indol derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | Kali-Chemie Pharma GmbH (DE) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | ASS1, C1S, FHIT | KCNH2 288/4885GPBAR1 1447/4885TLR8 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.